Del-Bel Elaine, Padovan-Neto Fernando E, Bortolanza Mariza, Tumas Vitor, Aguiar Aderbal S, Raisman-Vozari Rita, Prediger Rui D
Departamento MFP-Fisiologia, Faculdade de Odontologia de Ribeirao Preto, Universidade de Sao Paulo, USP, Center for Interdisciplinary Research on Applied Neurosciences (NAPNA), Ribeirao Preto, SP, Brazil.
Front Biosci (Elite Ed). 2015 Jan 1;7(1):168-92. doi: 10.2741/E726.
L-3,4-Dihydroxyphenylalanine (L-DOPA) remains the most effective symptomatic treatment of Parkinson's disease (PD). However, the long-term use of L-DOPA causes, in combination with disease progression, the development of motor complications termed L-DOPA-induced dyskinesia (LID). LID is the result of profound modifications in the functional organization of the basal ganglia circuitry. There is increasing evidence of the involvement of non-dopaminergic systems on the pathophysiology of LID. This raises the possibility of novel promising therapeutic approaches in the future, including agents that interfere with glutamatergic, serotonergic, adenosine, adrenergic, and cholinergic neurotransmission that are currently in preclinical testing or clinical development. Herein, we summarize the current knowledge of the pharmacology of LID in PD. More importantly, this review attempts to highlight the role of nitric oxide (NO) in PD and provide a comprehensive picture of recent preclinical findings from our group and others showing its potential involvement in dyskinesia.
左旋3,4-二羟基苯丙氨酸（L-多巴）仍然是帕金森病（PD）最有效的对症治疗药物。然而，长期使用L-多巴，再加上疾病进展，会导致出现称为L-多巴诱导的运动障碍（LID）的运动并发症。LID是基底神经节回路功能组织发生深刻改变的结果。越来越多的证据表明非多巴胺能系统参与了LID的病理生理学过程。这增加了未来出现新的有前景的治疗方法的可能性，包括目前正在临床前测试或临床开发中的干扰谷氨酸能、血清素能、腺苷能、肾上腺素能和胆碱能神经传递的药物。在此，我们总结了目前关于PD中LID药理学的知识。更重要的是，本综述试图强调一氧化氮（NO）在PD中的作用，并全面介绍我们小组和其他研究小组最近的临床前研究结果，这些结果表明其可能参与了运动障碍的发生。
